DNA testing for familial hypercholesterolemia: Improving disease recognition and patient care

American Journal of PharmacoGenomics

Volumn 2, Issue 4, 2002, Pages 253-262

  Vergopoulos, Athanasios ^a,b   Knoblauch, Hans ^a,b   Schuster, Herbert ^a,b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b INFOGEN GmbH   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E4; CYTOCHROME P450 3A4; FLUINDOSTATIN; GENE PRODUCT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVALONIC ACID; STATIN;

ACCOUNTING; ALLELE; AMPLICON; ATHEROSCLEROSIS; AUTOSOMAL INHERITANCE; CHOLESTEROL BLOOD LEVEL; DIAGNOSTIC APPROACH ROUTE; DNA DETERMINATION; DRUG METABOLISM; DRUG RESPONSE; DRUG USE; EARLY DIAGNOSIS; ELECTROPHORETIC MOBILITY; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; GENE IDENTIFICATION; GENE INTERACTION; GENE MUTATION; GENE SEGREGATION; GENE SEQUENCE; GENE TARGETING; GENETIC PROCEDURES; GENETIC SCREENING; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIVER; MORBIDITY; NONHUMAN; ONSET AGE; PATIENT INFORMATION; PHENOTYPE; PHENOTYPIC VARIATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEGREGATION ANALYSIS; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; ANIMAL; ETHICS; GENETICS; HYPERLIPOPROTEINEMIA TYPE 2; METHODOLOGY; MUTATION; PATIENT CARE; PHYSIOLOGY;

ANIMALS; GENETIC SCREENING; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; PATIENT CARE; PHENOTYPE;

EID: 1842868602     PISSN: 11752203     EISSN: None     Source Type: Journal    
DOI: 10.2165/00129785-200202040-00005     Document Type: Review

References (84)

1. The Low Density Lipeprotein Receptor (LDLR) Gene in Familial Hypercholesterolemia [Online]. Available from URL: http://www.ucl.ac.uk/fh [Accessed 2002 Jul 2]
2. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986; 232: 34-47
3. Hobbs H, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mutat 1992; 1: 445-66
4. Varret M, Rabes JP, Thiart R, et al. LDLR database (2nd ed.): New additions to the database and the software, and results of the first molecular analysis. Nucleic Acids Res 1998; 26: 248-52
5. Wilson DJ, Gahan M, Haddad L, et al. A world wide website for LDLR gene mutations in FH: Sequence-based, tabular, and direct submission data handling. Am J Cardiol 1998; 81: 1509-11
6. Tomlinson B, Lan IW. Hamilton-Craig I. Screening for familial hypercholesterolaemia: Funding is difficult to obtain but screening can be international. BMJ 2001; 322: 1061-2
7. Williams RR. Hunt SC, Schumacher MC, et al. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol 1993; 72: 171-6
8. Neil HAW, Hammond T, Huxley R, et al. Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: Prospective registry study. BMJ 2000; 321: 148-9
9. Umans-Eckenhausen MAW, Defesche JC, Sijbrands EJG, et al. Review of the first 5 years of screening for familial hypercholesterolemia in the Netherlands. Lancet 2001; 357: 165-8
10. Kastelein JJ. Screening for familial hypercholesterolemia: Effective, safe treatments and DNA testing make screening attractive. BMJ 2000 Dec; 321: 1483-4
11. Bhatnagar D, Morgan J, Siddiq S, et al. Outcome of case finding among relatives of patients with known heterozygous familial hyperchlolesterolaemia. BMJ 2000; 321: 1497-500
12. Mak YT, Pang CP, Tomlinson B, et al. Mutations in the low-density lipoprotein receptor gene in Chinese familial hypercholesterolemia patients. Arterioscler Thromb Vasc Biol 1998; 18: 1600-5
13. Williams RR, Hopkins PN, Stephenson S, et al. Primordial prevention of cardiovascular disease through applied genetics. Prev Med 1999 Dec; 29 (6 Pt 2): S41-9
14. Hobbs HH, Brown MS, Russell DW, et al. Deletion in the gene for the low-density-lipoprotein receptor in a majority of French Canadians with familial hypercholesterolemia. N Engl J Med 1987; 317: 734-7
15. Kotze MJ, Langenhoven E, Warnich L, et al. The molecular basis and diagnosis of familial hypercholesterolemia in South African Afrikaners. Ann Hum Genet 1991; 55: 115-21
16. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. BMJ 1991; 303: 893-6
17. Mortality in treated heterozygous familial hypercholesterolaemia: Implications for clinical management. Steering Committee on behalf of the Simon Broome Register Group. Atherosclerosis 1999; 142: 105-12
18. Nicholls P, Young I, Lyttle K, et al. Screening for familial hypercholesterolaemia: Early identification and treatment of patients is important [letter]. BMJ 2001; 322: 1062
19. Vohl MC, Gaudet D, Moorjani S, et al. Comparison of the effect of two low-density lipoprotein receptor class mutations on coronary heart disease among French-Canadian patients heterozygous for familial hypercholesterolemia. Eur J Clin Invest 1997; 27: 366-73
20. Hoeg JM. Homozygous familial hypercholesterolemia: A paradigm for phenotypic variation. Am J Cardiol 1993; 72: 11D-4D
21. Ferrieres J, Lambert J, Lussier-Cacan S, et al. Coronary artery disease in heretozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation. Circulation 1995; 92: 290-5
22. Kotze MJ, de Villiers WJS, Steyn K, et al. Phenotypic variation among familial hypercholesterolemic heterozygous for either one of two Afrikaner founder LDL receptor mutations. Arterioscler Thromb 1993; 13: 1460-8
23. Uiterwaal CSPM, Witterman JCM, De Brujin AM, et al. Families and natural history of lipids in childhood: An 18 year follow up study. Am J Epidemiol 1997; 145: 777-85
24. Ward AJ, O'Kane M, Nicholls DP, et al. A novel single base deletion in the LDLR gene (211 delG): Effect on serum lipid profiles and the influence of other genetic polymorphism in the ACE gene, apoE and apoB genes. Atherosclerosis 1996; 120: 83-91
25. Chaves FJ, Real JT, Garcia-Garcia AB, et al. Genetic diagnosis of Familial hypercholesterolemia in a South European outbred population: Influence of low-density-lipoprotein (LDL) receptor gene mutations on treatment response to simvastatin in total, LDL, and high-density lipoprotein cholesterol. J Clin Endocrinol Metab 2001; 86 (10): 4926-32
26. Watts GF. Postprandial lipaemia in familial hypercholesterolaemia: Clinical and metabolic significance. Atherosclerosis 2000; 148: 426-8
27. Real JT, Chaves FJ, Martinez-Uso I, et al. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolemia. Eur Heart J 2001; 22: 465-71
28. Gudnason V, Day INM, Humphries SE. Effect on plasma lipid levels of different classes of mutations in the low-density lipoprotein receptor gene ill patients with familial hypercholesterolemia. Arterioscler Thromb 1994; 17: 1717-22
29. Vuorio AF, Ojala JP, Sarna S, et al. Heterozygous familial hypercholesterolemia: The influence of the mutation type of the low density lipoprotein receptor gene and PvuII polymorphism of the normal allele on serum lipid levels and response to lovastatin treatment. J Intern Med 1995; 237: 43-8
30. Moorjani S, Roy M, Torres A, et al. Mutations of low density lipoprotein receptor gene, variation in plasma cholesterol, and expression of coronary heart disease in homozygous familial hypercholesterolemia. Lancet 1993; 341: 1303-6
31. Rabes JP, Varret M, Devillers M, et al. R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: e76-82
32. Sijbrands EJG, Westendorp RGJ, Defesche JC, et al. Mortality over two centuries in large pedigree with familial hypercholesterolemia: Family tree mortality study. BMJ 2001; 322: 1019-22
33. Williams RR. Hasstedt SJ, Wilson DE, et al. Evidence that men with familial hypercholesterolemia can avoid early coronary death: An analysis of 77 gene carriers in four Utah pedigrees. JAMA 1986; 255: 219-24
34. Vuorio AF, Turtola H, Piilahti KM, et al. Familial hypercholesterolemia in the Finnish North Karelia: A molecular, clinical, and genealogical study. Arterioscler Thromb Vase Biol 1997; 17: 3127-38
35. Silimane MN, Lestavel S, Sun X, et al. Fh-Fouassi a founder frameshift mutation in exon 10 of the LDL-receptor gene, associated with a mild phenotype in Tunisian families. Atherosclerosis 2001; 154: 557-65
36. Jansen ACM, van Wissen S, Defesche JC, et al. Phenotypic variability in familial hypercholesterolemia: Un update. Curr Opin Lipidol 2002; 13: 165-71
37. Emi M, Hegele R, Hopkins PN, et al. Effects of three genetic loci in a pedigree with multiple lipoprotein phenotypes. Arterioscler Thromb 1991; 11: 1349-55
38. Lambert M, Assouline L, Feoli-Fonseca JC. et al. Determinants of lipid level variability in French-canadian children with familial hyperchlolesterolemia. Arterioscler Thromb Vasc Biol 2001; 21: 979-84
39. Kastelein JJ, Ordovas JM, Wittekoek ME, et al. Two common mutations (DN9, N291S) in lipoprotein lipase: A cumulative analysis of their influence on plasma lipids and lipoproteins in men and women. Clin Genet 1999; 56: 297-305
40. Carmena-Ramon R, Ascaso JF, Real JT, et al. Association between the TaqIB polymorphism in the cholesteryl ester transfer protein gene locus and plasma lipoprotein levels in familial hypercholesterolemia. Metabolism 2001; 50: 651-6
41. Lundahl B, Leren TP, Ose L, et al. A functional polymorphism in the promoter region of the microsomal triglyceride transfer protein (MTP -493G/T) influences lipoprotein phenotype in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2000; 20: 1784-8
42. Coon H, Leppert MF, Kronenberg F, et al. Evidence for a major gene accounting for mild elevation in LDL cholesterol: The NHLBI Family Heart Study. Ann Hum Genet 1999; 63: 401-12
43. Hegele R. Monogenic dyslipidemias: Window on determinants of plasma lipoprotein metabolism. Am J Hum Genet 2001; 69: 1161-77
44. Garcia CK, Mues G, Liao Y, et al. Sequence diversity in genes of lipid metabolism. Genome Res 2001; 11: 1043-52
45. Knoblauch H, Muller-Myhsok B, Busjahn A, et al. A cholesterol-lowering gene maps to chromosome 13q. Am J Hum Genet 2000; 66: 157-66
46. Garcia CK, Wilund K, Arca M, et al. Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 2001; 292: 1394-8
47. Jeenah M, September W, Graadt van Roggen F, et al. Influence of specific mutations at the LDL receptor gene locus on the response to simvastatin therapy in Afrikaner patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1993; 98: 51-8
48. Kajinami K, Yagi K, Higashikata T, et al. Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia. Am J Cardiol 1998; 82: 113-7
49. Sijbrands EJ, Lombardi MP, Westerndrop RG, et al. Similar response to simvastatin in patients heterozygous for familial hypercholesterolemia with mRNA negative and mRNA positive mutations. Atherosclerosis 1998; 136: 247-54
50. Karayan L, Qiu S, Betard C, et al. Response to HMG CoA reductase inhibitors in heterozygous familial hypercholesterolemia due to the 10-kb deletion (French Canadian mutation) of the LDL-receptor gene. Arterioscler Thromb 1994; 14: 1258-63
51. Leren TP, Hjermann I. Is responsiveness to lovastatin in familial hypercholesterolemia influenced by the specific mutation in the low density lipoprotein receptor gene? Eur J Clin Invest 1995; 25: 967-73
52. Leitersdorf E, Eisenberg E, Eliav O, et al. Genetic determinants of responsiveness to HMG-CoA reductase inhibitor fluvastatin in patients with molecularly defined heterozygous familial hypercholesterolemia. Circulation 1993; 87: 35-44
53. Betard C, Kessling AM, Roy M, et al. Influence of genetic variability in the non-deletion LDL-receptor allele on phenotypic variation in French Canadian familial hypercholesterolemia heterozygotes sharing a "null" LDL-receptor gene defect. Atherosclerosis 1996; 119: 43-55
54. O'Malley JP, Illingworth DR. The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia. Metabolism 1990; 39: 150-4
55. De Knijff P, Stalenhoef AFH, Mol MJTM, et al. Influence of apoE polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia. Atherosclerosis 1990; 63: 89-97
56. Berglund I, Wiklund O, Eggertsen G, et al. Apolipoprotein E phenotypes in familial hypercholesterolemia: Importance for expression of disease and response to therapy. J Intern Med 1993; 233: 173-8
57. Carmena R, Roederer G, Mailloux H, et al. The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism. Metabolism 1993; 42: 895-901
58. O'Neill FH, Patel DD, Knight BL, et al. Determinants of variable response to statin treatment in patients with refractory familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2001; 21: 832-7
59. Fischer V, Johanson L, Heitz I, et al. The 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor fluvastatin: Effect on human cytochrome P-450 and implications for metabolic drugs interactions. Drug Metab Dispos 1999; 27: 410-6
60. Furuya H, Fernandez-Salguero P, Gregory W, et al. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. Pharmacogenetics 1995; 5: 389-92
61. Haddad L. Day IN, Hunt S. et al. Evidence for a third genetic locus causing familial hypercholesterolemia: A non-LDLR, non-ApoB kindred. J Lipid Res 1999; 40: 1113-22
62. Varret M, Rabes JP, Saint-Jore B, et al. A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-32. Am J Hum Genet 1999; 64: 1378-87
63. Norman D, Sun XM, Bournon M, et al. Characterisation of a novel cellular defect in patients with phenotypic homozygous familial hyperchoelsterolemia. J Clin Invest 1999; 104: 619-28
64. Hunt SC, Hopkins PN, Bulka K, et al. Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred. Arterioscler Thromb Vasc Biol 2000; 20: 1089-93
65. Ciccarese M, Pacifico A, Tonolo G, et al. A new locus for autosomal recessive hypercholesterolemia maps to human chromosome 15q25-q26. Am J Hum Genet 2000; 66: 453-60
66. Heath KE, Humphries SE, Middleton-Price H, et al. A molecular genetic service for diagnosing individuals with familial hypercholesterolemia (FH) in the United Kingdom. Eur J Hum Genet 2001; 9: 244-52
67. Jackson PR, Wallis EJ, Haq IU, et al. Statins for primary prevention: At what coronary risk is safety assured? Br J Clin Pharmacol 2001; 52: 439-46
68. Goldman L, Goldman PA, Williams LW, et al. Cost-effectiveness considerations in the treatment of heterozygous familial hypercholesterolemia with medications. Am J Cardiol 1993; 72 (10): 75D-9D
69. Tonstad S. Familial hypercholesterolaemia: A pilot study of parents' and children's concerns. Acta Paediatr 1996; 85 (11): 1307-13
70. Tonstad S, Novik TS, Vandvik IH. Psychosocial function during treatment for familial hypercholesterolemia. Pediatrics 1996; 98: 249-55
71. Andersen LK, Jensen HK, Juul S, et al. Patients' attitudes toward detection of heterozygous familial hypercholesterolemia. Arch Intern Med 1997; 157 (5): 553-60
72. The American Society of Human Genetics Social Issues Subcommittee on Familial Disclosure. ASHG statement: Professional disclosure of familial genetic information. Am J Hum Genet 1998; 62: 474-83
73. Executive summary of the third report of the National cholesterol Education Program (NCEP) Expert panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult treatment panel III). JAMA 2001; 285: 2486-97
74. Cahilly C, Ballantyne CM, Lim DS, et al. A variant of p22phox, involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res 2000; 86: 391-5
75. Leus FR, Zwart M, Kastelein JJ, et al. PON2 gene variants are associated with clinical manifestations of cardiovascular disease in familial hypercholesterolemia patients. Atherosclerosis 2001; 154: 641-9
76. Sebestjen M, Zegura B, Guzic-Salobir B, et al. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia. Wien Klin Wochenschr 2001; 113: 113-8
77. O'Malley JP, Maslen CL, Illingworth DR. Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 1998; 97: 1780-3
78. Greenspan P, Yu H, Mao F, et al. Cholesterol deposition in macrophages: Foam cell formation mediated by cholesterol-enriched oxidized low density lipoprotein. J Lipid Res 1997; 38: 101-9
79. Suzuki H, Kurihara Y, Takeya M, et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 1997; 386: 292-6
80. Tontonoz P, Nagy L, Alvarez JGA, et al. PPARγ promotes monocyte/macrophage: Differentiation and uptake of oxidized LDL. Cell 1998; 93: 241-52
81. Reape TJ, Groot PH. Chemokines and atherosclerosis. Atherosclerosis 1999; 147: 213-5
82. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease: Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5
83. Blake GJ, Ridker PM. High sensitivity C-reactive protein for predicting cardiovascular disease: An inflammatory hypothesis. Eur Heart J 2001; 22: 349-52
84. Danesh J, Collins R, Appleby P, et al. Association of fibrinogen, C-reactive protein, albumin, or leucocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 1998; 279: 1477-82